Amount of qualified individuals: CDEC mentioned the uncertainty in the amount of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be labeled as possessing mild or average ailment might have a serious bleeding https://assisiw344tcj3.wikitelevisions.com/user